0000827809 false 0000827809 2020-01-15 2020-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549









Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): January 16, 2020




Novelion Therapeutics Inc.

(Exact Name of Registrant as specified in its charter)




British Columbia, Canada   000-17082   98-0455702
(State or Other Jurisdiction
of Incorporation)
File Number)
  (IRS Employer
Identification No.)


c/o Norton Rose Fulbright

1800 - 510 West Georgia Street, Vancouver, BC V6B 0M3 Canada

(Address of principal executive offices)


Registrant’s telephone number, including area code: (877) 764-3131



(Former name or former address, if changed since last report.)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Shares, without par value NVLNF OTC Markets


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 1.03. Bankruptcy or Receivership.


As previously disclosed by Novelion Therapeutics Inc. (the “Company”) in the Current Reports on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on November 5, 2019 and November 22, 2019, at the Company’s 2019 Annual General Meeting held November 5, 2019 (the “Meeting”), shareholders voted in favor of all proposals contained in the Company’s proxy statement dated October 3, 2019 (the “Proxy Statement”), including the approval of a special resolution authorizing the voluntary liquidation and dissolution of the Company (the “Liquidation”) pursuant to the Business Corporations Act (British Columbia) (the "BCBCA"); the plan of liquidation and distribution substantially in the form attached as Schedule A to the Proxy Statement (the “Liquidation Plan”); and one or more distributions to shareholders of any remaining property of the Company under the Liquidation. Shareholders also approved an ordinary resolution appointing Alvarez & Marsal Canada Inc. as the liquidator of the Company pursuant to Section 319(2)(a) of the BCBCA (the “Liquidator”). Subsequent to receiving such shareholder approval of the Liquidation, on November 18, 2019, the Company filed application materials with the Supreme Court of British Columbia (the “Court”) which sought, among other things, affirmation of the appointment of the Liquidator, a stay of proceedings against the Company, and approval of a Court-supervised process to solicit and determine any claims against the Company. In addition, the Company sought approval of a Court-ordered charge on the Company’s property as security for the fees of the Liquidator, the Liquidator’s counsel, if any, and the Company’s counsel.


On January 9, 2020, the Court granted the orders sought by the Company in connection with the Liquidation, and the Company filed a Statement of Intent to Liquidate with the British Columbia Registrar of Companies establishing the definitive effective date and time for the commencement of implementation of the Liquidation as 5:00 p.m. Pacific Time on January 16, 2020 (the “Effective Date”). As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator (the “Liquidator”) and charged with overseeing all aspects of the Liquidation.


The terms and provisions of the Liquidation Plan have been previously disclosed in the Proxy Statement, with the Liquidation Plan attached as Schedule A to the Proxy Statement.


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 16, 2020, concurrent with the Liquidator’s appointment, (i) Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and (ii) Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company, effective immediately.


Item 8.01. Other Events.


On January 16, 2020, the Company issued a press release regarding the Liquidation, which press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Description
99.1   Press Release, dated January 16, 2020.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Novelion Therapeutics Inc.
  By: /s/ Alvarez & Marsal Canada Inc.               
  Name: Alvarez & Marsal Canada Inc.
  Title: Liquidator, acting solely in such capacity and not in its personal capacity


Date:  January 21, 2020






EX-99.1 2 tm203649d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1




Novelion Therapeutics Confirms Commencement
of Voluntary Liquidation


VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. (“Novelion” or the “Company”) today announced that the implementation of the Company’s voluntary liquidation (the “Liquidation”) commenced at 5:00 p.m. Pacific Time today, January 16, 2020 (the “Effective Date”).


As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator (the “Liquidator”) and charged with overseeing all aspects of the Liquidation. Concurrent with the Liquidator’s appointment: (i) Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and (ii) Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company.


Shareholders and other interested parties should visit www.alvarezandmarsal.com/novelion for continuing information about Novelion, the Liquidation and related matters.


As of the Effective Date, the Company’s transfer agent has closed the Company’s stock transfer books and discontinued recording transfers, and registered shareholders are no longer able to transfer record ownership of their shares. Registered shareholders on the Company’s stock transfer books (“Registered Holders”) as of the Effective Date will be entitled to a pro-rata share of any distribution to shareholders in the Liquidation.


Cautionary Information Regarding the Company’s Securities


Any distributions made in the Liquidation will be paid and delivered only to Registered Holders as of the Effective Date, and beneficial holders of common shares will be entitled to receive any distributions only through and from the applicable Registered Holder of their shares. Shareholders whose shares in Novelion are held in a brokerage firm or with a securities dealer, trust company, bank or another similar organization, are encouraged to reach out to their broker, dealer, trust, bank or other agent with any questions relating to the processes or requirements for receiving any such distributions if and when they are made.


The Company believes, but cannot assure, that OTC and other trading in the Company’s common shares will be suspended or otherwise cease as of the Effective Date or shortly thereafter. The Company cautions that investors who may seek to trade in Novelion common shares or other securities after the Effective Date (to the extent such trading is available), including on any secondary markets, do so at substantial risk to their investment.


The Company continues to caution that trading in the Company’s securities (to the extent such trading is available) remains highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual value realized, if any, by holders of the Company’s securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.





Forward-Looking Statements


Certain statements in this press release constitute “forward-looking statements” and “forward-looking information” within the meaning of applicable laws and regulations, including U.S. and Canadian securities laws. Any statements contained herein which do not describe historical facts, including, but not limited to, the Liquidator’s actions with respect to the Liquidation and any orders of the Court related to same, the amount, timing and nature of any distribution as part of the Liquidation, the ultimate outcome of the Liquidation process, and expectations and beliefs related to trading in and the market and record of holders of Novelion common shares after the Effective Date, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.


Such risks and uncertainties include, among others, the impact of any determinations of the Court and the actions of the Liquidator undertaken as part of the Liquidation, the possibility that there could be claims or actions that result from the claims process conducted as part of the Liquidation or otherwise, the possibility that such claims and actions could be costly to defend and could have negative outcomes, the possibility that actual expenses and claims that result from the Liquidation will be greater than anticipated, and the potential impact of any volatility in the market price of the shares of Amryt Equity held by the Company, any or all of which could materially reduce the availability of assets available for distribution to shareholders, as well as those risks identified in Novelion’s filings with the Securities and Exchange Commission (the “SEC”), including the definitive proxy statement filed on October 3, 2019, which are available on the SEC’s website at www.sec.gov. The impact from any such risks and uncertainties could materially reduce or eliminate the availability of assets available for distribution to shareholders.


Novelion cautions investors and others not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, Novelion undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


Pinky Law
Vice President
Alvarez & Marsal Canada Inc.
(604) 637-7446





EX-101.SCH 3 nvlnf-20200116.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nvlnf-20200116_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nvlnf-20200116_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm203649d1_ex99-1img01.jpg GRAPHIC begin 644 tm203649d1_ex99-1img01.jpg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end EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-005619-xbrl.zip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end XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 tm203649d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000827809 2020-01-15 2020-01-16 iso4217:USD shares iso4217:USD shares 0000827809 false 8-K 2020-01-16 Novelion Therapeutics Inc. A1 000-17082 98-0455702 c/o Norton Rose Fulbright 1800 - 510 West Georgia Street Vancouver BC V6B 0M3 CA 877 764-3131 false false false false Common Shares, without par value NVLNF false XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://novelion.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm203649d1_8k.htm nvlnf-20200116.xsd nvlnf-20200116_lab.xml nvlnf-20200116_pre.xml tm203649d1_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm203649d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm203649d1_8k.htm" ] }, "labelLink": { "local": [ "nvlnf-20200116_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nvlnf-20200116_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nvlnf-20200116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nvlnf", "nsuri": "http://novelion.com/20200116", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm203649d1_8k.htm", "contextRef": "From2020-01-15to2020-01-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://novelion.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm203649d1_8k.htm", "contextRef": "From2020-01-15to2020-01-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://novelion.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Jan. 16, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 16, 2020
Entity File Number 000-17082
Entity Registrant Name Novelion Therapeutics Inc.
Entity Central Index Key 0000827809
Entity Tax Identification Number 98-0455702
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One c/o Norton Rose Fulbright
Entity Address, Address Line Two 1800 - 510 West Georgia Street
Entity Address, City or Town Vancouver
Entity Address, Country CA
Entity Address, Postal Zip Code BC V6B 0M3
City Area Code 877
Local Phone Number 764-3131
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol NVLNF
Entity Emerging Growth Company false